+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
UCB (Union chimique belge) - logo

UCB is a global biopharmaceutical company that focuses on neurology and immunology. The company’s core products are Cimzia, Vimpat, Neupro, Keppra and Briviact, and they are also preparing the launch of a potential medicine to help patients with osteoporosis. It offers products for the treatment of central nervous system disorders, allergy and respiratory diseases, and immune and inflammatory disorders. UCB employs over 7,000 people and is based in Brussels, Belgium.

From
From
From
From
Epilepsy Drugs - Global Strategic Business Report - Product Thumbnail Image

Epilepsy Drugs - Global Strategic Business Report

  • Report
  • April 2024
  • 93 Pages
  • Global
From
Krabbe Disease Treatment - Global Strategic Business Report - Product Thumbnail Image

Krabbe Disease Treatment - Global Strategic Business Report

  • Report
  • April 2024
  • 194 Pages
  • Global
From
From
From
From
US Axial Spondyloarthritis Market outlook to 2028 - Product Thumbnail Image

US Axial Spondyloarthritis Market outlook to 2028

  • Report
  • October 2023
  • 85 Pages
  • United States
From
Psoriasis - Pipeline Insight, 2024 - Product Thumbnail Image

Psoriasis - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 100 Pages
  • Global
From
Global Rheumatoid Arthritis Drugs Market 2024-2028 - Product Thumbnail Image

Global Rheumatoid Arthritis Drugs Market 2024-2028

  • Report
  • October 2023
  • 162 Pages
  • Global
From
Loading Indicator